DBV Technologies SA

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

29 июл 2025 16:08:23 Источник Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

28 июл 2025 16:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

22 июл 2025 16:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

25 июн 2025 16:15:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming EAACI Congress 2025

12 июн 2025 16:05:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

11 июн 2025 16:30:00 Источник Nasdaq GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

04 июн 2025 16:32:09 Источник Nasdaq GlobeNewswire

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

03 июн 2025 16:30:00 Источник Nasdaq GlobeNewswire

Combined General Meeting of June 11, 2025

15 май 2025 16:30:00 Источник Nasdaq GlobeNewswire

Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025

06 май 2025 16:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

05 май 2025 16:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Reports First Quarter 2025 Financial Results

30 апр 2025 16:00:00 Источник Nasdaq GlobeNewswire

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

11 апр 2025 16:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

27 мар 2025 22:30:05 Источник Nasdaq GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

24 мар 2025 02:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

25 фев 2025 16:01:00 Источник Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

13 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

08 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

11 дек 2024 16:05:00 Источник Nasdaq GlobeNewswire

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024

02 дек 2024 16:30:00 Источник Nasdaq GlobeNewswire